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Background and purpose   Discussion persists as to whether obe-
sity negatively influences the outcome of hip arthroplasty. We 
performed a meta-analysis with the primary research question 
of whether obesity has a negative effect on short- and long-term 
outcome of total hip arthroplasty. 
Methods   We searched the literature and included studies com-
paring the outcome of hip arthroplasty in different weight groups. 
The methodology of the studies included was scored according to 
the Cochrane guidelines. We extracted and pooled the data. For 
continuous data, we calculated a weighted mean difference and 
for dichotomous variables we calculated a weighted odds ratio 
(OR). Heterogeneity was calculated using I2 statistics. 
Results   15 studies were eligible for data extraction. In obese 
patients, dislocation of the hip (OR = 0.54, 95% CI: 0.38–0.75) (10 
studies, n = 8,634), aseptic loosening (OR = 0.64, CI: 0.43–0.96) (6 
studies, n = 5,137), infection (OR = 0.3, CI: 0.19–0.49) (10 studies, 
n = 7,500), and venous thromboembolism (OR = 0.56, CI: 0.32–
0.98) (7 studies, n = 3,716) occurred more often. Concerning septic 
loosening and intraoperative fractures, no statistically significant 
differences were found, possibly due to low power. Subjective out-
come measurements did not allow pooling because of high hetero-
geneity (I2 = 68%). 
Interpretation   Obesity appears to have a negative influence on 
the outcome of total hip replacement. 
 
Obesity has reached epidemic proportions in the USA, and the 
rest of the well-developed world is expected to follow. Since 
obesity is a well-documented risk factor for the development 
of osteoarthritis (Sturmer et al. 2000, Flugsrud et al. 2006), an 
increased need for joint arthroplasty in obese people can be 
expected. Surgery on obese patients can lead to longer duration 
of the operative procedures themselves, with higher complica-
tion rates and longer hospital stays, and some authors have 
even suggested refusal of elective surgery in obese patients 
(Fehring et al. 2007). 
A controversy that has flared up during the last decennium is 
whether obesity might also influence the functional results and 
survival of total hip arthroplasty (THA), with studies show-
ing either different or similar outcome compared to normal-
weight patients. For both outcomes, different explanations 
have been postulated. McClung et al. (2000), for example, 
found that a higher BMI was associated with lower activity, 
resulting in less polyethylene wear in these patients, since 
wear is a function of use and not time. On the other hand, 
higher forces acting on the prosthesis in obese patients may 
lead to early loosening. 
Generally, a person with a BMI between 25 and 30 is cat-
egorized as overweight, and someone with a BMI of greater 
than 30 is obese. In this meta-analysis, we evaluated the 
results of all published trials comparing outcome and survival 
of primary THA between different BMI groups (BMI of < 30 
and of > 30). Our main research question was whether obesity 
has a negative effect on the short- and long-term outcome of 
total hip arthroplasty. 
 
Methods
Our search strategy was performed according to the recom-
mendations of the Cochrane collaboration (Lefebvre et al. 
2008). We searched the databases of Pubmed/Medline, the 
Cochrane Database of Systematic Reviews, and Embase from 
1970 to 2010 regarding publications on obesity and THA. 
The search terms “arthroplasty”, “hip”, “weight”, “BMI”, and 
“obesity” were used. Furthermore, the lists of references of 
retrieved publications were manually checked for additional 
studies potentially meeting the inclusion criteria but not found 
by the electronic search. 2 investigators (DH and MK) inde-
pendently reviewed the literature to identify relevant articles 
for full review. From the full text, using the above-mentioned 
criteria, the reviewers independently selected articles for inclu-
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resolved by consensus, with arbitration by a third author (MS) 
when differences remained. Studies were included if they were 
comparative trials comparing the outcome of primary THA 
between different BMI groups. We included studies involving 
all types of cemented and non-cemented total hip prosthesis 
designs. Review articles, expert opinions, surgical techniques, 
and abstracts from scientific meetings were excluded. Only 
articles written in English were included. Studies were not 
blinded regarding author, affiliation, or source (Jadad et al. 
1996). This systematic review and meta-analysis were done 
according to the PRISMA guidelines.
Our primary research question was to determine whether 
the outcome of primary THA is influenced by BMI. As short-
term outcome, we selected the following complications: infec-
tion, hematoma, venous thromboembolism, and perioperative 
fractures. As medium- to long-term outcome parameters, we 
selected: dislocation, septic loosening, aseptic loosening, and 
subjective outcome at follow-up.
Methodology of the randomized clinical trials and con-
trolled clinical trials was independently assessed by 2 review-
ers (MK and MS) using the list of criteria recommended by the 
Cochrane Collaboration Back Review Group (van Tulder et al. 
2003). Disagreement was resolved by group assessment. This 
frequently used list consists of 11 criteria for internal validity: 
3 criteria related to selection bias, 4 criteria for performance 
bias, 2 criteria for attrition bias, and 2 for detection bias. Stud-
ies are considered to be of sufficient quality if at least 6 of the 
11 validity criteria are met. 
Statistics
The data from the studies included were extracted by one 
reviewer (DH) using a pre-piloted data extraction tool, and they 
were verified by the second reviewer (MS). Then the available 
data from the selected studies were pooled using the Review 
Manager software from the Cochrane Collaboration. For out-
come variables with a continuous nature, a weighted mean dif-
ference was calculated with 95% confidence interval (CI). For 
the dichotomous variables, a weighted odds ratio (OR) with 
95% CI was calculated using Review Manager software.
For the studies where continuous variables were reported 
with a range, the SD was calculated using the method described 
by Walter and Yao (2007). The heterogeneity of the studies 
included was calculated using I2 statistics. This measurement 
describes the percentage of variation across studies that is due 
to heterogeneity rather than chance (Higgins et al. 2003). We 
also assessed heterogeneity by means of a chi-square analysis, 
whereby a p-value of < 0.1 was considered to be suggestive of 
statistical heterogeneity.
Results
After consensus was reached, 15 studies were included for 
data analysis (Table 1 and Figure 1). 
Table 1. The trials included
Author   Study type   Groups (BMI)   n    Follow-up   Outcome reported
 
Andrew et al. 2008  prospective  < 30, 30–40, > 40  1,421  mean 5 years  Survival, loosening, dislocation, complications, OHS
Bergschmidt et al. 2010  prospective  < 25, 25–30, 30–35  100  mean 2 years  HHS, WOMAC
Chee et al. 2010  prospective  < 30, > 30  110  mean 5 years  Survival, loosening, dislocation, complications 
Dowsey et al. 2008  retrospective  < 25, 25–30, > 30  1,207  1 year  Infection
Ibrahim et al. 2005  retrospective  < 25, 30–40  459  1 year  Survival, loosening, dislocation, complications
Kessler et al. 2007  prospective  < 25, 25–30, > 30  67  3 months  Complications, WOMAC
Lehman et al. 1994  retrospective  < 30, 30–40, > 40  324  > 2 year  Survival, loosening, dislocation, complications
Lübbeke et al. 2007  prospective  < 30, > 30  2,636  > 5 years  Survival, loosening, dislocation, complications, HHS
McLaughlin et al. 2006  retrospective  < 30, > 30  285  > 10 years  Survival, loosening, dislocation, complications
Namba et al. 2005  retrospective  < 35, > 35  1,071  1 year  Loosening, dislocation, complications
Paterno et al. 1997  retrospective  < 30, > 30  380  > 2 years  Dislocation
Sadr Azodi et al. 2008  implant register < 25, 25–30, > 30   2,106  mean 2 years  Dislocation
Søballe et al. 1987  retrospective  < 27, > 27  141  > 5 years  Survival, loosening, dislocation, complications
Yeung et al. 2010  retrospective  < 30, > 30  134  2–10 years  Survival, loosening, Harris hip score
Figure 1. PRISMA flow diagram.
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2003) (Figure 5). 
Of the early complications, 
infection was documented 
most consistently and precisely 
throughout the studies. 10 stud-
ies containing 7,500 patients 
could be pooled, giving an OR of 
0.3 (CI: 0.19–0.49) and showing 
that infection occurred 3 times 
more often in obese individuals 
(Figure 6). Presence of a hema-
Figure 2. Forest plot, dislocations
Figure 3. Forest plot, septic loosening.
Figure 4. Forest plot, aseptic loosening.
Figure 5. Forrest plot, Harris hip score. 
Not all of the studies allowed retrieval of poolable data 
for the defined outcomes. Regarding dislocation, 10 studies 
(involving 8,634 patients) could be pooled and showed that 
dislocation occurred more often in patients with a BMI of > 
30 (OR = 0.5, CI: 0.38–0.75). Heterogeneity was absent with 
an I2 of 0% (Figure 2). No subanalysis was performed for dif-
ferent types of prosthesis and approach, although all studies 
evaluated comparable approaches and implants. 
toma was not always mentioned or well-defined; thus, pooling 
was possible in only 3 studies with 1,961 patients, which did 
not reveal any statistically significant difference between the 
weight groups (OR = 1.5, CI: 0.66–3.5) (Figure 7). Venous 
thromboembolism (VTE) was often classified as deep vein 
thrombosis and pulmonary embolism. Since the underlying 
pathological mechanism is the same, we combined these num-
bers for pooling. Data from 3,716 patients in a total of 7 stud-
Aseptic and septic loosening in the 
different groups were well documented 
in 6 of the studies. Septic loosening 
could be analyzed in 3,816 patients, 
which resulted in an OR of 0.6 (CI: 
0.26–1.33), meaning that there was 
no statistically significant difference 
(Figure 3). For aseptic loosening, data 
from 5,137 patients could be pooled, 
and showed more aseptic loosening in 
patients with a BMI of > 30 (OR = 0.6, 
CI: 0.43–0.96); the forest plot is shown 
in Figure 4. Duration of the follow-up 
was not included in this analysis, but 
the amount of prosthesic loosening is 
certainly influenced by time. Since all 
studies included evaluated loosening 
in obese and non-obese patients over a 
similar follow-up period, the duration 
of the follow-up could be disregarded 
when pooling these events. 
Of the subjective outcomes, only the 
Harris hip score (HHS) was used often 
enough to allow pooling. Only follow-
up periods of 2 years or more were 
pooled in this analysis, which showed a 
statistically significant mean difference 
of 5 (CI: 3.1–5.9) in 1,805 patients in 5 
studies. Heterogeneity of these data was 
high, with an I2 of 68%, which did not 
allow pooling of the data. Furthermore, 
the minimal clinically important dif-
ference for the HHS is reported to be 4 
points, which means that this difference 
was clinically relevant (Hoeksma et al. 420  Acta Orthopaedica 2011; 82 (4): 417–422
ies showed that VTE is more common in obese patients (OR = 
0.6, CI: 0.32–0.98) (Figure 8). 
Of the several intraoperative complications, fracture corre-
lated best with difficulty of the procedure. However, pooling 
resulted in less than 1,000 patients in 3 studies, which in turn 
resulted in no statistically significant difference, possibly due 
to lack of power (Figure 9).
Of all the studies included, only 5 reported the preoperative 
co-morbidity, which gave a 2-fold higher co-morbidity in the 
obese (OR = 0.5, CI: 0.44–0.59) (5,747 
patients, with an I2 of 55%). Correction 
for the presence of co-morbidity on the 
occurrence of complications is not pos-
sible in this meta-analysis.
Methodology in all the studies 
included scored less than 6 points, scor-
ing all of them as low quality (Table 2). 
However, since all were comparable in 
quality, pooling of these studies was 
allowed. 
Discussion
We found that the risk of perform-
ing THR on obese patients is certainly 
higher. Not only is the complication 
rate 3-fold higher; the longevity of the 
implant is also impaired. We therefore 
inform patients who are obese of these 
risks, and refer them to a multidisci-
plinary obesity outpatient clinic. If 
they do not lose weight, an advantage 
is that all co-morbidity of the patient 
is analyzed and his/her medical condi-
tion is optimized. We do not withhold 
THR from these patients, but we inform 
them of the risks associated with obesity 
regarding THR. 
It is well known that obese people 
have more co-morbidity than people of 
normal weight. Theoretically, this co-
morbidity could be the reason for the 
higher complication rates. It is not stated 
that obese people without co-morbidity 
have the same risk as obese people 
with co-morbidity, which of course is 
also true for the non-obese. However, 
if co-morbidity is the reason for higher 
complications and not the obesity itself, 
correction for the presence of co-mor-
bidity should be performed on the data, 
especially since the studies that mention 
preoperative co-morbidity show a 2-fold 
Figure 6. Forest plot, infection. 
Figure 7. Forest plot, hematoma. 
Figure 8. Forest plot, venous thromboembolism.
Figure 9. Forest plot, perioperative fracture. 
higher incidence in the obese. Correcting for the presence of 
co-morbidity on the occurrence of complications was not pos-
sible in this meta-analysis. 
The choice of cutoff point for BMI is based on a consensus 
that 30 is the borderline between obesity and non-obesity, but 
a BMI of 25 or more already means being overweight. Today, 
a BMI of between 25 and 30 is much more common and is 
beginning to be judged as more or less normal. To define the 
effect of weight on the outcome, it would be better to use the Acta Orthopaedica 2011; 82 (4): 417–422  421
BMI as a continuous variable in the analysis. Not all studies 
used a BMI of 30 as the borderline; the oldest study of Søballe 
et al. (1987) used 27, a value that was popular in the 1980s. 
Namba et al. (2005) used a cutoff point of 35, and one study 
compared normal-weight patients (with a BMI of < 25) with 
obese patients (with a BMI of > 30), leaving out the patients 
with a BMI of between 25 and 30 (Ibrahim et al. 2005).
Previous studies have suggested that dislocation occurs 
more often in obese people (Paterno et al. 1997, Sadr et al. 
2008). Correct placement of components may be more dif-
ficult in the obese. However, 2 studies have shown that com-
ponent orientation is similar in obese patients and in those of 
normal weight (Pirard and De Lint 2007, Todkar 2008), but the 
power of these studies was probably not sufficient to answer 
this question. Another explanation for the higher dislocation 
rates in obese patients could be that surgery is more difficult 
and of longer duration, leading to more soft tissue damage 
and, subsequently, less intrinsic stability in the first few weeks 
and months. 
We found a 3-times higher infection risk in obese patients. 
We noted, however, that the rates of septic loosening were not 
any different, which might indicate that only superficial infec-
tions occurred more often. Another explanation may be the 
lack of power, because of 24 events in approximately 4,000 
patients. Another problem is that often the deep and superfi-
cial infections were not reported separately. 
The difference between preoperative and postoperative 
Harris hip score may be more informative about the success 
of THR in the obese than simply HHS at follow-up, since 
it is not unlikely that obese patients score lower on subjec-
tive outcome measurements than normal-weight individuals, 
purely from the fact that they are obese and not as a reflection 
of the surgical result. In all studies reporting HHS, the only 
outcome measurement used frequently enough to consider 
pooling it was only reported as a follow-up value. Thus, the 
improvement in HHS could not be compared between groups. 
The HHS at follow-up had a heterogeneity that was too high 
to allow pooling. Apart from this, the measured difference in 
HHS between obese and normal-weight patients was barely 
higher than the minimal clinically important difference, which 
is 4 points for the HHS. This meta-analysis cannot therefore 
answer the question of whether subjective outcome differs 
between normal-weight and obese patients. 
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